ClinicalTrials.gg
CompletedNCT06136598Updated Mar 19, 2026

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

A Phase 1 interventional study of Opevesostat and Dexamethasone in Prostatic Neoplasms and Metastatic Castration-Resistant Prostate Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Prostatic Neoplasms by Merck & Co., Inc — 4 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms · Merck & Co., Inc.

Enrollment
17th of 22
14 · median 93
Started
2024
with 2 others
Phase 1
6 of 22
none open now
Registered
16th of 22
by date

Among the 22 studies in Prostatic Neoplasms by Merck & Co., Inc, this one is the 17th largest by enrollment, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 16th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 22 studies in Prostatic Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Prostatic Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the safety and tolerability of opevesostat in the treatment of male Chinese participants with metastatic castration-resistant prostate cancer (mCRPC) and to characterize the pharmacokinetic profile of opevesostat. There are no formal hypotheses to be tested in this study.

03

Conditions studied

  • Prostatic Neoplasms
  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Has or cytologically confirmed adenocarcinoma of the prostate without small cell histology.
  • Has prostate cancer while receiving androgen deprivation therapy (ADT), or post-bilateral orchiectomy, within 6 months before screening.
  • Has evidence of progression >4 weeks since last flutamide treatment or >6 weeks since last bicalutamide or nilutamide treatment.
  • Has evidence of disease documented by either bone lesions on bone scan and/or soft tissue shown by CT/MRI.
  • Has disease that progressed during or after treatment with at least 1 line of next-generation hormonal agents (NHAs) for hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC) for at least 8 weeks (at least 14 weeks for participants with bone progression).
  • Has received at least 1 line of taxane-based chemotherapy for HSPC or CRPC and have had progressed disease during or on treatment, or refused or ineligible to receive chemotherapy.
  • Has a of >3 months.

Exclusion criteria

Exclusion Criteria:

  • Has history of a second , unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
  • Has presence of gastrointestinal condition, e.g. malabsorption, that might affect the adsorption of study intervention.
  • Has a history of pituitary dysfunction.
  • Has poorly controlled diabetes mellitus.
  • Has active or unstable cardio/cerebro-vascular disease, including thromboembolic events.
  • Has undergone major surgery, including local prostate intervention (except prostate ), within 4 weeks of the date of allocation.
  • Has received an anticancer monoclonal antibody (mAb) within 4 weeks of allocation, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of allocation.
  • Received prior systemic anticancer therapy including agents within 4 weeks before the date of allocation.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any form of therapy within 7 days prior to the start of study intervention.
  • Has a known active central nervous system (CNS) and/or carcinomatous meningitis.
  • Has an active disease that has required systemic treatment in the past 2 years.
  • Has a history of or current (HIV) infection.
  • Has a concurrent or virus infection.
  • Has a history of allogenic tissue or solid organ transplant.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Opevesostat

    Participants will receive opevesostat by oral tablets twice daily plus dexamethasone and fludrocortisone by oral tablets once daily continuously until unacceptable toxicity or documented progression. Hydrocortisone will also be provided to participants for use as rescue medication.

    Drug: Opevesostat · Drug: Dexamethasone · Drug: Fludrocortisone · Drug: Hydrocortisone

Interventions

  • Tablets to be taken orally.

    Also known as: MK-5684

  • Tablets to be taken orally

    Also known as: Dexamethasone acetate

  • Tablets to be taken orally.

    Also known as: Fludrocortisone acetate

  • Tablet to be taken orally as a rescue medication.

    Also known as: Hydrocortisone acetate

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.

    Time frame: Up to approximately 20 months

  2. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.

    Time frame: Up to approximately 20 months

  3. Maximum Plasma Concentration (Cmax) of opevesostat

    Blood samples will be collected at pre-specified timepoints to determine the Cmax of opevesostat.

    Time frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose

  4. Time to Maximum Plasma Concentration (Tmax) of opevesostat

    Blood samples will be collected at pre-specified timepoints to determine the Tmax of opevesostat.

    Time frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose

  5. Area Under the Curve from Time 0 to 12 hours postdose (AUC0-12) of opevesostat

    Blood samples will be collected at pre-specified timepoints to determine the AUC0-12 of opevesostat.

    Time frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose

  6. Apparent Volume of Distribution (Vz/F) of opevesostat

    Blood samples will be collected at pre-specified timepoints to determine the Vz/F of opevesostat.

    Time frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose

  7. Oral Clearance (CL/F) of opevesostat

    Blood samples will be collected at pre-specified timepoints to determine the CL/F of opevesostat.

    Time frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose

  8. Half-Life (t1/2) of opevesostat

    Blood samples will be collected at pre-specified timepoints to determine the t1/2 of opevesostat.

    Time frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose

Secondary outcomes

  1. Prostate-specific Antigen (PSA) Response Rate

    The PSA response rate is defined as the percentage of participants in the analysis population with a reduction in PSA level of ≥50% measured twice ≥3 weeks apart.

    Time frame: Up to approximately 37 months

  2. Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    rPFS is defined as the time from first dose of study intervention to radiographic progression per PCWG-modified RECIST 1.1 as assessed by the investigator OR death due to any cause, whichever occurs first.

    Time frame: Up to approximately 37 months

  3. Objective Response Rate (ORR) Per PCWG-modified RECIST 1.1

    ORR is defined as the percentage of participants who have a best overall response of either confirmed Complete Response (CR: disappearance of all target lesions) or a confirmed Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per PCWG-modified RECIST 1.1 as assessed by the investigator.

    Time frame: Up to approximately 37 months

  4. Duration of Response (DOR) Per PCWG-modified RECIST 1.1

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per PCWG-modified RECIST 1.1, DOR is defined as the time from first documented evidence of confirmed CR or PR until disease progression or death from any cause, whichever occurs first.

    Time frame: Up to approximately 37 months

  5. Overall Survival (OS)

    OS is defined as time from first dose of study intervention to death due to any cause.

    Time frame: Up to approximately 37 months

  6. Blood Concentrations of Steroids

    Blood samples collected at multiple timepoints after the administration of opevesostat will be used to determine the blood concentrations of steroids.

    Time frame: At designated timepoints (up to approximately 37 months)

07

Study locations

3 sites
  • Peking University First Hospital-Urology ( Site 0001)
    Beijing, Beijing Municipality 100034, China
  • Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003)
    Guangzhou, Guangdong 510700, China
  • Tongji Hospital Tongji Medical,Science & Technology ( Site 0002)
    Wuhan, Hubei 430000, China
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Mar 2026, 25 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 25 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Nov 18, 2023
StartActual
Jan 30, 2024
Primary completionActual
Mar 9, 2026
CompletionActual
Mar 9, 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06136598
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Jan 30, 2024
Primary completion
Mar 9, 2026
Completion
Mar 9, 2026
Last update
Mar 19, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opevesostat

Start the discussion